{"id":84791,"date":"2026-01-29T12:31:37","date_gmt":"2026-01-29T10:31:37","guid":{"rendered":"https:\/\/gulftech-news.com\/en\/?p=84791"},"modified":"2026-01-29T12:31:38","modified_gmt":"2026-01-29T10:31:38","slug":"lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/","title":{"rendered":"Lilly&#8217;s sofetabart mipitecan receives U.S. FDA&#8217;s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\"><\/h1>\n\n\n\n<p><\/p>\n\n\n\n<p><a href=\"https:\/\/en.wikipedia.org\/wiki\/Eli_Lilly_and_Company\">Eli Lilly<\/a> and Company\u00a0(NYSE: LLY) today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a novel folate receptor alpha (FR\u03b1) antibody-drug conjugate (ADC) that uses proprietary linker technology and an exatecan payload.\u00a0<\/p>\n\n\n\n<p>Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).<\/p>\n\n\n\n<p>&#8220;Platinum-resistant ovarian cancer remains one of the most challenging settings in gynecologic oncology, with limited treatment options and poor outcomes for patients,&#8221; said&nbsp;Bhavana Pothuri, M.D., professor of Obstetrics\/Gynecology and Medicine at&nbsp;NYU Grossman School of Medicine,&nbsp;NYU Langone Health&nbsp;and director of Clinical Trials Office at the&nbsp;Perlmutter Cancer Center. &#8220;The Breakthrough Therapy designation and preliminary clinical data for sofetabart mipitecan across all levels of FR\u03b1 expression are encouraging and point to its potential as a meaningful treatment option for patients.&#8221;<\/p>\n\n\n\n<p>&#8220;We are pleased the FDA has granted Breakthrough Therapy designation for sofetabart mipitecan, reflecting the significant unmet need in platinum-resistant ovarian cancer and the promising initial results shown in our Phase 1 study,&#8221; said&nbsp;Jacob Van Naarden, executive vice president, and president of Lilly Oncology and head of corporate business development. &#8220;Building on compelling results generated to date, we&#8217;ve initiated our Phase 3 FRAmework-01 trial with the goal of bringing a potential therapeutic option to patients with advanced ovarian cancer, across all levels of folate receptor expression.&#8221;<\/p>\n\n\n\n<p>The FDA Breakthrough Therapy designation is based on encouraging preliminary results from the Phase 1a\/b study. Lilly&nbsp;<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4599075-1&amp;h=1524849968&amp;u=https%3A%2F%2Finvestor.lilly.com%2Fnews-releases%2Fnews-release-details%2Flilly-presents-first-clinical-data-its-investigational-next&amp;a=presented+initial+Phase+1+results\" target=\"_blank\" rel=\"noreferrer noopener\">presented initial Phase 1 results<\/a>&nbsp;at the 2025 ASCO Annual Meeting in June and&nbsp;<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4599075-1&amp;h=733241189&amp;u=https%3A%2F%2Fassets.ctfassets.net%2Fmpejy6umgthp%2F1uJG8ot1tMr2W9eo2xUUoT%2Fdf033b6b8622bcdde35ae515e27e945a%2FVV-ONCPT1_ESMO2025_RAY-COQUARD_RESULTS_RESISTANT_OVARIAN_DV-034288_V1.2.pdf&amp;a=updated+data\" target=\"_blank\" rel=\"noreferrer noopener\">updated data<\/a>&nbsp;at the 2025&nbsp;ESMO Congress&nbsp;in October, showing responses at all dose levels and across all FR\u03b1 expression levels, including in patients who progressed on prior mirvetuximab soravtansine. These initial data also indicate a promising tolerability profile with low rates of interstitial lung disease, peripheral neuropathy, and alopecia, and no significant ocular toxicity.<\/p>\n\n\n\n<p>Sofetabart mipitecan recently advanced into the Phase 3 FRAmework-01 study (<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4599075-1&amp;h=237027431&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT07213804&amp;a=NCT07213804\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07213804<\/a>), a global trial investigating the treatment as a monotherapy in patients with platinum resistant ovarian cancer (PROC), and in combination with bevacizumab in patients with platinum-sensitive ovarian cancer (PSOC). Lilly is conducting the FRAmework-01 study in partnership with the&nbsp;European Network for Gynaecological Oncological Trial&nbsp;groups (ENGOT &#8211; lead groups GINECO\/NOGGO e.V.), the&nbsp;GOG Foundation&nbsp;(GOG), and the&nbsp;Asia-Pacific Gynecologic Oncology Trials Group&nbsp;(APGOT)<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company\u00a0(NYSE: LLY) today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a novel folate receptor &hellip;<\/p>\n","protected":false},"author":2,"featured_media":84792,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2,439],"tags":[5046,3058,5047,5048],"class_list":["post-84791","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-research-universities","tag-cancer","tag-eli-lilly","tag-fda","tag-sofetabart-mipitecan"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company\u00a0(NYSE: LLY) today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Breakthrough\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company\u00a0(NYSE: LLY) today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Breakthrough\" \/>\n<meta property=\"og:url\" content=\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Gulf Tech News\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T10:31:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-29T10:31:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/Lilly-1-1.jpg?v=1769682351\" \/>\n\t<meta property=\"og:image:width\" content=\"886\" \/>\n\t<meta property=\"og:image:height\" content=\"497\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"bessan helmi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"bessan helmi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/\",\"url\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/\",\"name\":\"lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy\",\"isPartOf\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/Lilly-1-1.jpg?v=1769682351\",\"datePublished\":\"2026-01-29T10:31:37+00:00\",\"dateModified\":\"2026-01-29T10:31:38+00:00\",\"author\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c\"},\"description\":\"Eli Lilly and Company\u00a0(NYSE: LLY) today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Breakthrough\",\"breadcrumb\":{\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#primaryimage\",\"url\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/Lilly-1-1.jpg?v=1769682351\",\"contentUrl\":\"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/Lilly-1-1.jpg?v=1769682351\",\"width\":886,\"height\":497,\"caption\":\"Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/gulftech-news.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly&#8217;s sofetabart mipitecan receives U.S. FDA&#8217;s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#website\",\"url\":\"https:\/\/gulftech-news.com\/en\/\",\"name\":\"Gulf Tech News\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/gulftech-news.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c\",\"name\":\"bessan helmi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g\",\"caption\":\"bessan helmi\"},\"url\":\"https:\/\/gulftech-news.com\/en\/author\/bessan-helmi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy","description":"Eli Lilly and Company\u00a0(NYSE: LLY) today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Breakthrough","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy","og_description":"Eli Lilly and Company\u00a0(NYSE: LLY) today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Breakthrough","og_url":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/","og_site_name":"Gulf Tech News","article_published_time":"2026-01-29T10:31:37+00:00","article_modified_time":"2026-01-29T10:31:38+00:00","og_image":[{"width":886,"height":497,"url":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/Lilly-1-1.jpg?v=1769682351","type":"image\/jpeg"}],"author":"bessan helmi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"bessan helmi","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/","url":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/","name":"lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy","isPartOf":{"@id":"https:\/\/gulftech-news.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#primaryimage"},"image":{"@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/Lilly-1-1.jpg?v=1769682351","datePublished":"2026-01-29T10:31:37+00:00","dateModified":"2026-01-29T10:31:38+00:00","author":{"@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c"},"description":"Eli Lilly and Company\u00a0(NYSE: LLY) today announced that the\u00a0U.S. Food and Drug Administration\u00a0(FDA) has granted Breakthrough","breadcrumb":{"@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#primaryimage","url":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/Lilly-1-1.jpg?v=1769682351","contentUrl":"https:\/\/gulftech-news.com\/en\/wp-content\/uploads\/2026\/01\/Lilly-1-1.jpg?v=1769682351","width":886,"height":497,"caption":"Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/gulftech-news.com\/en\/2026\/01\/29\/lillys-sofetabart-mipitecan-receives-u-s-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/gulftech-news.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lilly&#8217;s sofetabart mipitecan receives U.S. FDA&#8217;s Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer"}]},{"@type":"WebSite","@id":"https:\/\/gulftech-news.com\/en\/#website","url":"https:\/\/gulftech-news.com\/en\/","name":"Gulf Tech News","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/gulftech-news.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/c033626e357b2f7e127eac0570ddc05c","name":"bessan helmi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/gulftech-news.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bb1e09a6f094e0fa605073926f8ad9eb228a8b0aacd381fda782c562612428cf?s=96&d=mm&r=g","caption":"bessan helmi"},"url":"https:\/\/gulftech-news.com\/en\/author\/bessan-helmi\/"}]}},"_links":{"self":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/84791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/comments?post=84791"}],"version-history":[{"count":1,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/84791\/revisions"}],"predecessor-version":[{"id":84793,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/posts\/84791\/revisions\/84793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/media\/84792"}],"wp:attachment":[{"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/media?parent=84791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/categories?post=84791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/gulftech-news.com\/en\/wp-json\/wp\/v2\/tags?post=84791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}